Verrica Pharmaceuticals Inc.
VRCA
$0.4891
$0.02264.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -82.70% | -161.06% | 2,744.51% | 10,240.54% | 2,823.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.70% | -161.06% | 2,744.51% | 10,240.54% | 2,823.53% |
| Cost of Revenue | -39.39% | 61.11% | -34.12% | 116.82% | 565.60% |
| Gross Profit | 34.76% | -183.72% | 123.17% | 18.41% | -514.79% |
| SG&A Expenses | -41.87% | -19.80% | 178.29% | 278.31% | 432.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.33% | -29.48% | 72.77% | 214.69% | 259.72% |
| Operating Income | 45.01% | 13.43% | -30.91% | -162.36% | -231.65% |
| Income Before Tax | 34.18% | 7.83% | -56.38% | -208.56% | -314.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.18% | 7.83% | -56.38% | -208.56% | -314.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.18% | 7.83% | -56.38% | -208.56% | -314.94% |
| EBIT | 45.01% | 13.43% | -30.91% | -162.36% | -231.65% |
| EBITDA | 45.54% | 14.00% | -30.21% | -163.51% | -236.32% |
| EPS Basic | 54.73% | 9.27% | -54.45% | -185.70% | -268.07% |
| Normalized Basic EPS | 49.78% | 9.24% | -54.41% | -185.68% | -230.27% |
| EPS Diluted | 54.73% | 9.27% | -54.45% | -185.70% | -262.30% |
| Normalized Diluted EPS | 49.78% | 9.24% | -54.41% | -185.68% | -230.27% |
| Average Basic Shares Outstanding | 45.38% | 1.59% | 1.27% | 8.04% | 12.70% |
| Average Diluted Shares Outstanding | 45.38% | 1.59% | 1.27% | 8.04% | 12.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |